Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 24

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 24
---
 time the number of shares to be included in each such series, to fix the rights, preferences and privileges
of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the
number of shares of any such series, but not below the number of shares of such series then outstanding.

<div align='center'>15</div>

Our board of directors may
authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights
of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions
and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control
that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and
other rights of the holders of common stock.

There currently are no provisions
under our amended and restated articles of incorporation or under any other contractual obligations whereby we are required to issue or
sell shares of preferred stock and we have no present plans to issue any shares of preferred stock.

Anti-Takeover Effects of Provisions of Our Articles of Incorporation, Our Bylaws and Washington Law

Provisions in our articles
of incorporation, our bylaws and under Washington law may delay or prevent an acquisition of us or a change in our management, including
transactions in which shareholders might otherwise receive a premium for their shares or transactions that our shareholders might otherwise
deem to be in their best interests. Certain of the provisions of our articles of incorporation and bylaws with an anti-takeover effect
are summarized below. These provisions may frustrate or prevent any attempts by our shareholders to replace or remove our current management
by making it difficult for shareholders to replace members of our board of directors, which is responsible for appointing the members
of our management.

Additionally, because we are
incorporated in Washington, we are governed by the provisions of Chapter 23B.19 of the WBCA, which, among other things, prohibits a “target
corporation,” with certain exceptions, from engaging in certain “significant business transactions” for a period of
five years after the share acquisition by an “acquiring person”, unless (a) the significant business transaction is approved
by a majority of the members of the target corporation’s board of directors prior to the time of the acquiring person’s share
acquisition or (b)